Absci Corporation (ABSI)
NMS · Healthcare · Biotechnology
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
About Absci Corporation
Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities. The company was founded in 2011 and is headquartered in Vancouver, Washington.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 593K | 378K | 650K | 215K |
| Operating Income | -31.4M | -30.2M | -36.1M | -30.8M |
| Net Income | -30.6M | -28.7M | -29.6M | -29.6M |
| Diluted EPS | $-0.24 | $-0.20 | $-0.20 | $-0.19 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 5.7M | 5.7M | 4.5M | 2.8M |
| Operating Income | -106.8M | -94.2M | -108.9M | -125.4M |
| Net Income | -104.9M | -110.6M | -103.1M | -115.2M |
| Diluted EPS | $-1.15 | $-1.20 | $-0.94 | $-0.84 |